Abstract
Purpose
The purpose of this study is to assess the late oral complications and the role of salivary gland hypofunction in the severity of mucosal reaction in nonsurgical head and neck cancer patients, submitted to radiotherapy with or without chemotherapy.
Methods and materials
Five hundred fifteen charts from patients treated between 2005 and 2009 were reviewed, and 41 patients met the inclusion criteria. Salivary gland function was assessed using a simplified grading system (GSX) and sialometry. Late effects were assessed using the Common Toxicity Criteria (CTC Version 2.0).
Results
The average follow-up was 17.1 (4–51) months. A statistical correlation was found for whole salivary flow rates and the average CTC grades for the mucous membrane. Both unstimulated/stimulated whole salivary flow rates (<0.09 mL/min) were identified as potential risk factors (p < 0.05) and an independent predictor for late mucous membrane toxicity (≥grade 2). A significant correlation was also found between unstimulated salivary flow rates—GSX scores (p = 0.001) and CTC grades for salivary glands. Eighty-five percent of the patients were classified as suffering from salivary gland hypofunction, as well as 58.2 % considered dryness of the mouth the most debilitating complication.
Conclusions
Considering the late effects assessed, the salivary gland hypofunction was the most significant and received the highest morbidity graduation (grade 2/grade 3); xerostomia was also considered the most debilitating complication after treatment. Data show the role of salivary gland hypofunction in the severity of late mucous membrane complication.
Similar content being viewed by others
References
Shah JP, Gil Z (2009) Current concepts in management of oral cancer—surgery. Oral Oncol 45:394–401
Gallegos-Hernández JF (2006) Head and neck cancer. Risk factors and prevention. Cir Cir 74(4):287–93
McMahon S, Chen AY (2003) Head and neck cancer. Cancer Metastasis Rev 22:21–24
Döbrõssy L (2005) Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 24:9–17
Chua DTT, Tian Y, Wei WI (2007) Late oral complications following radiotherapy for head and neck cancers. Expert Rev Anticancer Ther 7(9):1215–1224
Zackrisson B, Mercke C, Strander H et al (2003) A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 42(5):443–461
Al-Sarraf M, Pajak TF, Byhardt RW et al (1997) Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 37(4):777–782
Newlin HE, Amdur RJ, Riggs CE et al (2010) Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 116:4533–4540
Bentzen SM, Rosenthal DI, Weymuller EA, Trotti A (2007) Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventions. Int J Radiat Oncol Biol Phys 69(2 Suppl):S79–S82
Pignon JP, Maître AL, Bourhis J et al (2007) Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 69(2 Suppl):S112–S114
Langendijk JA (2007) New developments in radiotherapy of head and neck cancer: higher precision with less patient discomfort? Radiother Oncol 85:1–6
Trotti A (2000) Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 47(1):1–12
Kawashima M (2004) Chemoradiotherapy for head and neck cancer: current status and perspectives. Int J Clin Oncol 9:421–434
Dirix P, Abbeel S, Vanstraelen B et al (2009) Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose–effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 75(2):385–392
Perlmutter MA, Johnson JT, Snyderman CH et al (2002) Functional outcomes after treatment of squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 128:887–891
Eisbruch A, Rhodus RD et al (2003) The prevention and treatment of radiotherapy-induced xerostomia. Semin Radiat Oncol 13(3):302–308
Jensen SB, Pedersen AM, Reibel J, Nauntofte B (2003) Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11:207–225
Saad ED, Hoff PM, Carnelós RP et al (2002) Critérios Comuns de Toxicidade do Instituto Nacional de Câncer dos Estados Unidos (Common toxicity criteria of the National Cancer Institute). Rev Bras Cancerol 48(1):63–96
Cancer Therapy Evaluation Program (1999) Common Toxicity Criteria, Version 2.0. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf. Accessed 20 Jan 2010
Eisbrush A, Rhodus N, Rosenthal D et al (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13(3):226–234
Radiation Therapy Oncology Group (1999) A phase III study to test the efficacy of the prophylatic use of oral pilocarpine to reduce hyposalivation and mucositis associated with curative radiation therapy in head and neck cancer patients. RTOG97-09. Philadelphia, PA: Radiation Therapy Oncology Group. www.rtog.org/members/protocols/97-09/97-09.pdf. Accessed 20 Jan 2010
Navazesh M, Christensen CM (1982) A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 61(10):1158–62
Adelstein DJ (2007) Concurrent chemoradiotherapy in the management of squamous cell cancer of the oropharynx: current standards and future directions. Int J Radiat Oncol Biol Phys 69(2 Suppl):S37–S39
Furness S, Glenny AM, Worthington HV et al (2010) Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews, 9: CD006386
Stone HB, Coleman CN, Anscher MS, McBride WH (2003) Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 4:529–536
Givens DJ, Karnell LH, Gupta AK et al (2009) Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 135(12):1209–1217
Withers HR, Peters LJ, Taylor JMG (1995) Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: patterns of fractionation study of radiobiology. Int J Radiat Oncol Biol Phys 33(3):563–568
Citrin D, Mansueti J, Likhacheva A (2009) Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 74(4):1040–1046
Chen AM, Li BQ, Jennelle RLS et al (2010) Late esophageal toxicity after radiation therapy for head and neck cancer. Head Neck 32:178–183
Power DA (2005) Late effects of radiotherapy: how to assess and improve outcomes. Br J Radiol 78:150–152
Cooper JS, Fu K, Marks J, Silverman S (1995) Late effects of radiation therapy in the head and neck region. Int J Radiation Oncology Biol Phys 31(5):1141–1164
Vissink A, Jansma J, Spijkervet FKL (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14(3):199–212
Olmi P, Crispino S, Fallai C et al (2006) Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55(1):78–92
Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582–3589
Fischer DJ, Epstein JB (2008) Management of patients who have undergone head and neck cancer therapy. Dent Clin N Am 52:39–60
Epstein JB, Stevensen-Moore P (2001) Periodontal disease and periodontal management in patients with cancer. Oral Oncol 37:613–619
Eisbruch A, Kim HM, Terrel JE et al (2001) Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50(3):695–704
Sonis ST, Fey EG (2002) Oral complications of cancer therapy. Oncology 16(5):680–686
Yeh SA, Tang Y, Lui CC et al (2005) Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 62(3):672–679
Fu KK, Pajak TF, Marcial VA et al (1995) Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys 32(3):577–588
Sreebny LM, Valdini A (2006) Xerostomia. Part I: relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66(4):451–458
Guchelaar HJ, Vermes A, Meerwaldt JH (1997) Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 5:281–288
Kaplan I, Zuk-Paz L, Wolff A (2008) Association between salivary flow rates, oral symptoms, and oral mucosal status. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:235–41
Jensen SB et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 18(8):1061–79
Rose-Ped AM, Bellm LA, Epstein JB et al (2002) Complications of radiation therapy for head and neck cancers. Cancer Nurs 25(6):461–465
Acknowledgments
We are especially grateful for the patients for their participation in this study.
Conflict of interest
The authors report no actual or potential conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
This paper has been presented as an invited lecture at the 2010 MASCC/ISOO Symposium in Vancouver, Canada, on June 24–26, 2010.
Rights and permissions
About this article
Cite this article
Deboni, A.L., Giordani, A.J., Lopes, N.N.F. et al. Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer. Support Care Cancer 20, 2903–2911 (2012). https://doi.org/10.1007/s00520-012-1418-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-012-1418-7